CCA
GALT icon

Catalyst Capital Advisors’s Galectin Therapeutics GALT Stock Holding History

Catalyst Capital Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-675,000
Closed -$3.4M – 516
2014
Q3 		$3.4M Buy
+675,000
New +$5.26M 0.44% 72
2014
Q1 		– Sell
-204,000
Closed -$1.65M – 329
2013
Q4 		$1.65M Buy
+204,000
New +$1.88M 0.53% 74

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Catalyst Capital Advisors's GALT Position: Q4 2014 in Review

Catalyst Capital Advisors sold out of Galectin Therapeutics (GALT) in Q4 2014, closing a stake of 675,000 shares — an estimated $3.4M sold.

Catalyst Capital Advisors first reported a position in GALT in Q4 2013 and held it in 2 quarters. The position peaked at $3.4M in Q3 2014. 62 funds tracked by Wall St. Rank hold GALT as of Q4 2014.

  • Catalyst Capital Advisors reported no remaining Galectin Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Catalyst Capital Advisors sold 675,000 Galectin Therapeutics shares in Q4 2014, an estimated $3.4M.
  • Catalyst Capital Advisors first reported a position in Galectin Therapeutics in Q4 2013 and held it in 2 quarters.
  • Catalyst Capital Advisors's Galectin Therapeutics position peaked at $3.4M in Q3 2014.
  • 62 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2014.

Based on Catalyst Capital Advisors's 13F filing for Q4 2014, filed 10 Feb 2015.